Your browser doesn't support javascript.
loading
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Shore, Neal; Gazi, Mukaram; Pieczonka, Christopher; Heron, Sean; Modh, Rishi; Cahn, David; Belkoff, Laurence H; Berger, Aaron; Mazzarella, Brian; Veys, Joseph; Idom, Charles; Morris, David; Jayram, Gautam; Engelman, Alexander; Bukkapatnam, Raviender; Dato, Paul; Bevan-Thomas, Richard; Cornell, Robert; Wise, David R; Hardwick, Mary Kay; Hernandez, Ryan D; Rojahn, Susan; Layman, Paige; Hatchell, Kathryn E; Heald, Brandie; Nussbaum, Robert L; Nielsen, Sarah M; Esplin, Edward D.
Afiliação
  • Shore N; Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@auclinics.com.
  • Gazi M; University Urology Associates of New Jersey, Hamilton, NJ, USA.
  • Pieczonka C; Associated Medical Professionals, Syracuse, NY, USA.
  • Heron S; Advanced Urology Institute, St. Petersburg, FL, USA.
  • Modh R; Advanced Urology Institute, St. Petersburg, FL, USA.
  • Cahn D; Colorado Urology, Lakewood, CO, USA.
  • Belkoff LH; MidLantic Urology, Bala Cynwyd, PA, USA.
  • Berger A; Associated Urological Specialists, Chicago Ridge, IL, USA.
  • Mazzarella B; Urology Austin, Austin, TX, USA.
  • Veys J; North Georgia Urology, Dalton, GA, USA.
  • Idom C; North Georgia Urology, Dalton, GA, USA.
  • Morris D; Urology Associates, P.C., Nashville, TN, USA.
  • Jayram G; Urology Associates, P.C., Nashville, TN, USA.
  • Engelman A; TGH Cancer Institute, Tampa, FL, USA.
  • Bukkapatnam R; Florida Urology Partners, Tampa, FL, USA.
  • Dato P; Genesis Healthcare Partners, San Diego, CA, USA.
  • Bevan-Thomas R; Urology Partners, Arlington, TX, USA.
  • Cornell R; Urosurgery Houston, Houston, TX, USA.
  • Wise DR; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
  • Hardwick MK; Invitae Corporation, San Francisco, CA, USA.
  • Hernandez RD; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
  • Rojahn S; Invitae Corporation, San Francisco, CA, USA.
  • Layman P; Invitae Corporation, San Francisco, CA, USA.
  • Hatchell KE; Invitae Corporation, San Francisco, CA, USA.
  • Heald B; Invitae Corporation, San Francisco, CA, USA.
  • Nussbaum RL; Invitae Corporation, San Francisco, CA, USA; Volunteer Faculty, University of California San Francisco, San Francisco, CA, USA.
  • Nielsen SM; Invitae Corporation, San Francisco, CA, USA.
  • Esplin ED; Invitae Corporation, San Francisco, CA, USA.
Eur Urol Oncol ; 6(5): 477-483, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37574391
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Urol Oncol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Urol Oncol Ano de publicação: 2023 Tipo de documento: Article